tiprankstipranks
Trending News
More News >
StageZero Life Sciences Ltd (TSE:SZLS)
TSX:SZLS

StageZero Life Sciences Ltd (SZLS) Price & Analysis

Compare
60 Followers

SZLS Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.01%99.99%
Insiders
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors

SZLS FAQ

What was StageZero Life Sciences Ltd’s price range in the past 12 months?
StageZero Life Sciences Ltd lowest stock price was C$0.03 and its highest was C$0.04 in the past 12 months.
    What is StageZero Life Sciences Ltd’s market cap?
    StageZero Life Sciences Ltd’s market cap is C$4.94M.
      When is StageZero Life Sciences Ltd’s upcoming earnings report date?
      StageZero Life Sciences Ltd’s upcoming earnings report date is May 20, 2025 which is 24 days ago.
        How were StageZero Life Sciences Ltd’s earnings last quarter?
        Currently, no data Available
        Is StageZero Life Sciences Ltd overvalued?
        According to Wall Street analysts StageZero Life Sciences Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does StageZero Life Sciences Ltd pay dividends?
          StageZero Life Sciences Ltd does not currently pay dividends.
          What is StageZero Life Sciences Ltd’s EPS estimate?
          StageZero Life Sciences Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does StageZero Life Sciences Ltd have?
          StageZero Life Sciences Ltd has 123,553,050 shares outstanding.
            What happened to StageZero Life Sciences Ltd’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of StageZero Life Sciences Ltd?
            Currently, no hedge funds are holding shares in TSE:SZLS

            Company Description

            StageZero Life Sciences Ltd

            StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
            Similar Stocks
            Company
            Price & Change
            Follow
            BioMark Diagnostics
            Medivolve Inc
            Telo Genomics Corp
            Avricore Health
            Marvel Biosciences Corp
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis